Novartis-backed Gamida’s approval plans for cell therapy hits a snag with FDA asking for manufacturing data jkeenan Thu, 11/11/2021 – 09:22 More: Novartis-backed Gamida's approval plans for cell therapy hits a snag with FDA asking for manufacturing data Source: fierce
read moreOlumiant maintained a consistent safety profile in a long-term analysis of patients with rheumatoid arthritis More: New positive long-term data for JAK inhibitor Olumiant in RA Source: News
read moreNew guidelines from NICE, SIGN and the RCGP includes an update to original list of common symptoms More: Updated guidelines for managing long-term effects of COVID-19 published Source: News
read moreDecision follows the UK government’s termination of their deal with Valneva in September More: Valneva receives EU deal for COVID jab, and seeks apology from UK Source: News
read moreChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus More: University of Oxford begins human trials of Ebola vaccine Source: News
read moreJohnson & Johnson scores 60-day stay in high-profile talc litigation: report esagonowsky Wed, 11/10/2021 – 15:32 More: Johnson & Johnson scores 60-day stay in high-profile talc litigation: report Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals